Volumetric Analysis of In-Stent Intimal Hyperplasia in Diabetic Patients Treated with or without Abciximab: Results of the Diabetes Abciximab steNT Evaluation (DANTE) Randomized Trial

Circulation

Volumn 109, Issue 7, 2004, Pages 861-866

  Chaves, Áurea J ^a   Sousa, Amanda G M R ^a   Mattos, Luiz A ^a   Abizaid, Alexandre ^a   Staico, Rodolfo ^a   Feres, Fausto ^a   Centemero, Marinella ^a   Tanajura, Luiz F ^a   Abizaid, Andrea ^a   Maldonado, Ibraim Pinto Galo ^a   Seixas, Ana ^a   Costa, Marco A ^a   Paes, Ângela ^a   Mintz, Gary S ^b   Sousa, J Eduardo ^a  

^a INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

Diabetes mellitus; Glycoproteins; Stents; Ultrasonics

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; INSULIN; ORAL ANTIDIABETIC AGENT; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DIET RESTRICTION; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HUMAN; IMPLANTATION; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; INTRAVASCULAR ULTRASOUND; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STENT; STROKE; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; BRAZIL; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DIABETES MELLITUS, TYPE 2; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPERPLASIA; IMAGING, THREE-DIMENSIONAL; IMMUNOGLOBULIN FAB FRAGMENTS; INCIDENCE; LIFE TABLES; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; STENTS; SURGICAL PROCEDURES, ELECTIVE; TREATMENT FAILURE; TUNICA INTIMA; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 10744221624     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000116752.12261.D4     Document Type: Article

References (32)

1. Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998;32:1866-1873.
2. Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol. 1998;32:584-589.
3. Schofer J, Schluter M, Rau T, et al. Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study. J Am Coll Cardiol. 2000;35:1554-1559.
4. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
5. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
6. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
7. Bhatt DL, Marso SP, Lincoff AM, et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000;35:922-928.
8. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med. 1999;341:319-327.
9. Marso SP, Lincoff AM, Ellis SG, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus. Circulation. 1999;100:2477-2484.
10. Takagi T, Akasaka T, Yamamuro A, et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol. 2000;36:1529-1535.
11. Van Belle E, Bauters C, Hubert E, et al. Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation. 1997;96:1454-1460.
12. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: a serial intravascular ultrasound study. Circulation. 1997;95: 1366-1369.
13. Mehran R, Mintz GS, Hong MK, et al. Validation of the in vivo intravascular ultrasound measurement of in-stent neointimal hyperplasia volumes. J Am Coll Cardiol. 1998;32:794-799.
14. Serruys PW, Degertekin M, Tanabe K, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation. 2002;106:798-803.
15. Hong MK, Mintz GS, Lee CW, et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation. 2003;107:517-520.
16. Takeda Y, Tsuchikane E, Kobayashi T, et al. Effect of plaque debulking before stent implantation on in-stent neointimal proliferation: a serial 3-dimensional intravascular ultrasound study. Am Heart J. 2003;146: 175-182.
17. Willerson JT, Yao SK, McNatt J, et al. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci U S A. 1991;88:10624-10628.
18. Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol. 1996;28: 1643-1651.
19. Friedman RJ, Stemerman MB, Wenz B, et al. The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits: smooth muscle cell proliferation and re-endothelialization. J Clin Invest. 1977;60:1191-1201.
20. Tam SH, Sassoli PM, Jordan RE, et al. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation. 1998;98: 1085-1091.
21. Simon DI, Xu H, Ortlepp S, et al. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol. 1997;17:528-535.
22. Sajid M, Stouffer GA. The role of alpha(v)beta3 integrins in vascular healing. Thromb Haemost. 2002;87:187-193.
23. Schwarz M, Nordt T, Bode C, et al. The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2). Thromb Res. 2002;107:121-128.
24. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol. 1996;27: 528-535.
25. ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis. Circulation. 1999;100:799-806.
26. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/ IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000;35:915-921.
27. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
28. Kleiman NS, Lincoff AM, Kereiakes DJ, et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. Circulation. 1998;97:1912-1920.
29. Roffi M, Moliterno DJ, Meier B, et al. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention. Circulation. 2002;105: 2730-2736.
30. Hoffmann R, Jansen C, Konig A, et al. Stent design related neointimal tissue proliferation in human coronary arteries; an intravascular ultrasound study. Eur Heart J. 2001;22:2007-2014.
31. Steinhubl SR, Ellis SG, Wolski K, et al. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events. Circulation. 2001;103:1403-1409.
32. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.